Little House Capital LLC decreased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.5% during the 4th quarter, HoldingsChannel reports. The fund owned 23,428 shares of the company’s stock after selling 838 shares during the period. Johnson & Johnson comprises approximately 1.3% of Little House Capital LLC’s portfolio, making the stock its 22nd biggest holding. Little House Capital LLC’s holdings in Johnson & Johnson were worth $3,672,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of JNJ. 4J Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock valued at $444,000 after buying an additional 62 shares during the last quarter. My Personal CFO LLC raised its holdings in shares of Johnson & Johnson by 1.4% in the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after buying an additional 62 shares during the last quarter. Eagle Strategies LLC raised its holdings in shares of Johnson & Johnson by 1.8% in the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock valued at $563,000 after buying an additional 63 shares during the last quarter. Clearview Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock valued at $685,000 after buying an additional 64 shares during the last quarter. Finally, Brookmont Capital Management increased its position in Johnson & Johnson by 0.4% in the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on JNJ
Johnson & Johnson Price Performance
Shares of JNJ opened at $149.92 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.91 and a current ratio of 1.17. The stock has a 50 day simple moving average of $154.44 and a 200 day simple moving average of $155.08. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The firm has a market capitalization of $361.27 billion, a PE ratio of 9.35, a P/E/G ratio of 2.49 and a beta of 0.55.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the firm earned $2.68 EPS. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.31%. Johnson & Johnson’s payout ratio is presently 29.68%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
- Five stocks we like better than Johnson & Johnson
- Industrial Products Stocks Investing
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- How to Use Stock Screeners to Find Stocks
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- Golden Cross Stocks: Pattern, Examples and Charts
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.